Finally, our work supports ADAR1-mediated A-to-I editing as an important pathway in cancer progression, and highlights ADAR1, CDK13 and the edited CDK13-Q103R as potential targets for the development of new treatments for thyroid and other cancer types. Here, CDK13 is linked to thyroid gland disorder.